PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

MammaPrint and BluePrint NGS Results are Robust and Accurate for Patients with Early Stage Breast Cancer

  PUBLICATION: AMP 2020 AUTHORS: Douglas Kingma, Kasey Lawrence, Sahra Uygun, Camila Zanette, Helen Yang, Sammy Mee, Lorenza Mittempergher, Anke Witteveen, Leonie Delahaye, Bob Chan, Annuska Glas 1. Tennessee Oncology, Nashville, TN; 2. Agendia Inc, Irvine, CA; 3. Agendia NV, Amsterdam, The Netherlands Introduction: MammaPrint (MP) and BluePrint (BP) are Read More

ESMO 2020: UltraLow Data from the IKA Cohort

PUBLICATION: ESMO 2020 AUTHORS: Mark Opdam, Vincent van der Noort, Miranda Kleijn, Anuska Glas, Ingrid Mandjes, Dinja Kruger, Paul van Diest, Jan Vermorken, Harm van Tinteren, Sabine Linn Background: Adjuvant tamoxifen is widely used as endocrine treatment for oestrogen receptor positive (ER+) breast cancers (BC). Guidelines recommend the use of Read More

ESMO 2020 – Hallmarks of Cancer

PUBLICATION: ESMO 2020 AUTHORS: Josien C. Haan, Rajith Bhaskaran, Lorenza Mittempergher, Ersan Lujinovic, William Audeh, Frederique Penault-Llorca and Annuska M. Glas Background: MammaPrint® (MP) is a 70-gene based assay that stratifies early-stage breast cancer (EBC) patients into low and high-risk of relapse. BluePrint® (BP) is an 80-gene based assay that Read More

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial

PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Danalyn Byng, Sabine C. Linn, Katarzyna Jozwiak, Hendrik Koffijberg, Emiel J. Rutgers, Fatima Cardoso, Martine J. Piccart, Coralie Poncet, Laura J. van ’t Veer, Wim H. van Harten. Abstract: The clinical utility of the 70-gene signature (MammaPrint®) to guide chemotherapy Read More

Controlling Technical Variation Amongst 6693 Patient Microarrays of the Randomized MINDACT Trial

PUBLICATION: Communications Biology AUTHORS: Laurent Jacob, Anke Witteveen, Inès Beumer, Leonie Delahaye, Diederik Wehkamp, Jeroen van den Akker, Mireille Snel, Bob Chan, Arno Floore, Niels Bakx, Guido Brink, Coralie Poncet, Jan Bogaerts, Mauro Delorenzi, Martine Piccart, Emiel Rutgers, Fatima Cardoso, Terence Speed, Laura van ’t Veer, and Annuska Glas Abstract: Read More

ASCO 2020: Chemokine Signature

PUBLICATION: ASCO 20 AUTHORS: Hatem Soliman, Sangeetha Prabhakaran, Marilin Rosa, Charles Cox, Pat Whitworth, Sahra Uygun, Heather M. Kling, Erin B. Yoder, and William Audeh SUMMARY: Studies demonstrating the presence of immunoregulatory gene activation1 and tumor- infiltrating lymphocytes in the breast tumor microenvironment suggest the importance of an effective anti-tumor Read More